Why the study?
Does extended-duration enoxaparin reduce venous thromboembolism in ischemic stroke patients?
Population
389 ischemic stroke patients (a subgroup of 5,963 acutely ill medical patients with recently reduced mobility)
Comparison
Enoxaparin 40 mg daily for 28±4 days vs Placebo for 28±4 days
Design
RCT, randomized, double-blind
Follow-up
up to day 28 after randomization
Authors
Loading...
Supports extended enoxaparin for VTE prevention in ischemic stroke; extends prophylaxis evidence while requiring bleeding-risk assessment.
Does extended-duration enoxaparin reduce venous thromboembolism in ischemic stroke patients?
Extended-duration enoxaparin prophylaxis in ischemic stroke patients reduces venous thromboembolism risk but increases the risk of major bleeding.
Turpie et al. (2012) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: